Míriam Tarrado-Castellarnau

Míriam Tarrado-Castellarnau

Auto-generated profile, based on publicly available information

Míriam Tarrado-Castellarnau

Universitat de Barcelona 11 Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine of Universitat de Barcelona, Faculty of Biology Barcelona, Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SDSantiago Diaz-Moralli
Santiago Diaz-Moralli
MTMíriam Tarrado-Castellarnau
Míriam Tarrado-Castellarnau
AMAnibal Miranda
Anibal Miranda
MCMARTA CASCANTE
MARTA CASCANTE

28 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
MTMíriam Tarrado-Castellarnau
Míriam Tarrado-Castellarnau
PAPedro de Atauri
Pedro de Atauri
MCMARTA CASCANTE
MARTA CASCANTE
Oncogenic regulation of tumor metabolic reprogramming

1 October 2017 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
MTMíriam Tarrado‐Castellarnau
Míriam Tarrado‐Castellarnau
PAPedro de Atauri
Pedro de Atauri
JTJosep Tarragó-Celada
Josep Tarragó-Celada
JPJordi Perarnau
Jordi Perarnau
MYMariia Yuneva
Mariia Yuneva
MCMARTA CASCANTE
MARTA CASCANTE
Cyclin‐dependent kinases (CDK) are rational cancer therapeutic targets fraught with the development of acquired resistance by tumor cells. Through metabolic and transcriptomic analyses, we show that the inhibition of CDK4/6 leads to a metabolic reprogramming associated with gene networks orchestrated by the MYC transcription factor. Upon inhibition of CDK4/6, an accumulation of MYC protein ensues which explains an increased glutamine metabolism, activation of the mTOR pathway and blunting of HIF‐1α‐mediated responses to hypoxia. These MYC‐driven adaptations to CDK4/6 inhibition render cancer cells highly sensitive to inhibitors of MYC, glutaminase or mTOR and to hypoxia, demonstrating that metabolic adaptations to antiproliferative drugs unveil new vulnerabilities that can be exploited to overcome acquired drug tolerance and resistance by cancer cells.

27 September 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SDSantiago Diaz-Moralli
Santiago Diaz-Moralli
MTMiriam Tarrado-Castellarnau
Miriam Tarrado-Castellarnau
CACristina Alenda
Cristina Alenda
ACAntoni Castells
Antoni Castells
MCMARTA CASCANTE
MARTA CASCANTE
Transketolase-like 1 (TKTL1) induces glucose degradation through anaerobic pathways, even in presence of oxygen, favoring the malignant aerobic glycolytic phenotype characteristic of tumor cells. As TKTL1 appears to be a valid biomarker for cancer prognosis, the aim of the current study was to correlate its expression with tumor stage, probability of tumor recurrence and survival, in a series of colorectal cancer patients. Tumor tissues from 63 patients diagnosed with colorectal cancer at different stages of progression were analyzed for TKTL1 by immunohistochemistry. Staining was quantified by computational image analysis, and correlations between enzyme expression, local growth, lymph-node involvement and metastasis were assessed. The highest values for TKTL1 expression were detected in the group of stage III tumors, which showed significant differences from the other groups (Kruskal-Wallis test, P = 0.000008). Deeper analyses of T, N and M classifications revealed a weak correlation between local tumor growth and enzyme expression (Mann-Whitney test, P = 0.029), a significant association of the enzyme expression with lymph-node involvement (Mann-Whitney test, P = 0.0014) and a significant decrease in TKTL1 expression associated with metastasis (Mann-Whitney test, P = 0.0004). To our knowledge, few studies have explored the association between variations in TKTL1 expression in the primary tumor and metastasis formation. Here we report downregulation of enzyme expression when metastasis appears, and a correlation between enzyme expression and regional lymph-node involvement in colon cancer. This finding may improve our understanding of metastasis and lead to new and more efficient therapies against cancer.

4 November 2015 in Pharmacological Research
Verified
Journal Article
Open access
MTMíriam Tarrado-Castellarnau
Míriam Tarrado-Castellarnau
RCRoldán Cortés
Roldán Cortés
MZMiriam Zanuy
Miriam Zanuy
JTJosep Tarragó-Celada
Josep Tarragó-Celada
IPIbrahim H. Polat
Ibrahim H. Polat
MCMARTA CASCANTE
MARTA CASCANTE
Selenium supplement has been shown in clinical trials to reduce the risk of different cancers including lung carcinoma. Previous studies reported that the antiproliferative and pro-apoptotic activities of methylseleninic acid (MSA) in cancer cells could be mediated by inhibition of the PI3K pathway. A better understanding of the downstream cellular targets of MSA will provide information on its mechanism of action and will help to optimize its use in combination therapies with PI3K inhibitors. For this study, the effects of MSA on viability, cell cycle, metabolism, apoptosis, protein and mRNA expression, and reactive oxygen species production were analysed in A549 cells. FOXO3a subcellular localization was examined in A549 cells and in stably transfected human osteosarcoma U2foxRELOC cells. Our results demonstrate that MSA induces FOXO3a nuclear translocation in A549 cells and in U2OS cells that stably express GFP-FOXO3a. Interestingly, sodium selenite, another selenium compound, did not induce any significant effects on FOXO3a translocation despite inducing apoptosis. Single strand break of DNA, disruption of tumour cell metabolic adaptations, decrease in ROS production, and cell cycle arrest in G1 accompanied by induction of apoptosis are late events occurring after 24 h of MSA treatment in A549 cells. Our findings suggest that FOXO3a is a relevant mediator of the antiproliferative effects of MSA. This new evidence on the mechanistic action of MSA can open new avenues in exploiting its antitumour properties and in the optimal design of novel combination therapies. We present MSA as a promising chemotherapeutic agent with synergistic antiproliferative effects with cisplatin.

1 January 2014 in Metallomics
Verified
Journal Article
Open access
PDF file
RCRoldán Cortés
Roldán Cortés
MTMíriam Tarrado-Castellarnau
Míriam Tarrado-Castellarnau
DTDaniel Talancón
Daniel Talancón
CLConcepción López
Concepción López
Wolfgang LinkWolfgang Link
Wolfgang Link
MCMARTA CASCANTE
MARTA CASCANTE
Cisplatin is a platinum-based compound that acts as an alkylating agent and is used to treat a variety of malignant tumors including lung cancer. As c